• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Potential new heartburn drug studied at VUMC

Bioengineer by Bioengineer
February 26, 2020
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Vanderbilt University Medical Center


An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests.

Michael F. Vaezi, MD, PhD, MSc, director of the Center for Swallowing and Esophageal Disorders at Vanderbilt University Medical Center (VUMC), is corresponding author of the report published in the journal Gastroenterology. The study was conducted by Cambridge, Mass.-based Ironwood Pharmaceuticals.

“As a physician, it is very challenging to have nothing new to offer patients for whom standard treatments don’t work,” Vaezi said. “But the reality is many of our patients continue to struggle with frequent heartburn and regurgitation despite taking their PPIs.

“These data provide strong evidence that bile acid plays a key role in refractory GERD and that IW-3718 may have the potential to make a meaningful difference for patients,” he added.

Vaezi is professor of Medicine and clinical director of the Division of Gastroenterology, Hepatology and Nutrition in the Department of Medicine, Vanderbilt University School of Medicine. PPIs such as Prilosec and Nexium reduce the production of stomach acid.

Each week approximately 20% of the adult U.S. population reports GERD-related symptoms, including heartburn and regurgitation. Seven percent experience daily symptoms. Despite once-daily PPI therapy, the “mainstay” treatment for GERD, approximately 30% of patients continue to have symptoms.

IW-3718, which was developed by Ironwood Pharmaceuticals, combines an established drug that binds bile acids in the stomach with a technology that controls the release of drugs in the gastrointestinal tract. Bile acids have been shown to injure the lining of the esophagus as well as stomach and colon.

Fifty-two centers in the United States, including VUMC, participated in the randomized, double-blind study from March 2016 to April 2017. A total of 280 adult patients with refractory GERD were divided into four groups, one which received an inactive placebo and the others ascending doses of IW-3718 twice a day.

Heartburn symptoms were significantly reduced in the group receiving the highest dose, 1,500-milligrams twice daily, compared to the placebo group. Regurgitation symptoms also decreased. The drug was well tolerated. There were no drug-related serious adverse events.

“These results suggest that IW-3718 may provide a therapeutic option for refractory-GERD patients with continued symptoms despite once-daily PPI therapy,” the researchers concluded.

###

Media Contact
Craig Boerner
craig.boerner@vumc.org
615-322-4747

Related Journal Article

http://dx.doi.org/10.1053/j.gastro.2020.02.031

Tags: GastroenterologyInternal MedicineMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Intestinal Cellular Networks Govern Fibroblast Plasticity in Healing and Fibrotic Disease

Intestinal Cellular Networks Govern Fibroblast Plasticity in Healing and Fibrotic Disease

November 18, 2026
Extended-Interval Myeloma Antibody Therapy Safely Omits Repeat Step-Up Dosing in Cohort

Extended-Interval Myeloma Antibody Therapy Safely Omits Repeat Step-Up Dosing in Cohort

November 18, 2026

Hair Trace Element Profiling Links Micronutrients to Ulcerative Colitis Activity

November 18, 2026

Preventive Rimegepant Cuts Weekly Migraine Days in Half Within Two Weeks

November 18, 2026
Please login to join discussion

POPULAR NEWS

  • Over Forty Percent of Northeast Ethiopian Neonates Experience Early Cord Clamping

    Over Forty Percent of Northeast Ethiopian Neonates Experience Early Cord Clamping

    29 shares
    Share 12 Tweet 7
  • Biomimetic Hydroxyapatite Coating Restores Elastic Modulus in Recycled Aggregate Concrete

    29 shares
    Share 12 Tweet 7
  • Early Shoulder Mobilization Accelerates Initial Motion but Yields Equivalent Annual Outcomes

    29 shares
    Share 12 Tweet 7
  • SGLT2 Inhibitor Use Associated With Lower Proteinuria Rates During Bevacizumab Therapy

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Stem Cell Reports Named Official Meeting Journal for Organoids Are Us 2027

Nitrogen-Doped Graphene Underlayer Lowers Overpotential in Aluminum-Doped Hematite Water Splitting

Intestinal Cellular Networks Govern Fibroblast Plasticity in Healing and Fibrotic Disease

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.